NCT06284876

Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 416 (estimated)
• Sponsor: Il-Yang Pharm. Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate the non-inferiority of Ilaprazole 10 mg to the active control in prevention of NSAIDs-associated peptic ulcer, as assessed by the proportion of subjects with peptic ulcer by Week 24

Detailed description

Not provided

Conditions

• Peptic Ulcer

Interventions

Type	Name	Description
DRUG	Ilaprazole	Ilaprazole 10 mg
DRUG	Lansoprazole	Lansoprazole 15 mg
DRUG	Ilaprazole Placebo	Placebo of Ilaprazole 10 mg
DRUG	Lansoprazole Placebo	Placebo of Lansoprazole 15 mg

Timeline

• Start date: 2024-07-23
• Primary completion: 2026-08-30
• Completion: 2027-02-28
• First posted: 2024-02-29
• Last updated: 2025-05-30

Locations

2 sites across 1 country: South Korea